VINCERX PHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.72 USD | -3.73% |
|
-15.29% | -38.98% |
| Apr. 26 | Tech Rally Boosts Exchange-Traded Funds, Equity Futures Pre-Bell Friday | MT |
| Apr. 26 | Vincerx Pharma Prices Public Offering of Shares, Warrants | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 21.26M |
|---|---|---|---|---|---|
| Net income 2024 * | -28M | Net income 2025 * | -34M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.57
x | P/E ratio 2025 * |
-0.74
x | Employees | 42 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.53% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -3.73% | ||
| 1 week | -15.29% | ||
| Current month | -12.94% | ||
| 1 month | -23.38% | ||
| 3 months | -60.22% | ||
| Current year | -38.98% |
1 week
0.72
0.82
1 month
0.660.99
Current year
0.669.37
1 year
0.619.37
3 years
0.6118.43
5 years
0.6126.75
10 years
0.6126.75
| Managers | Title | Age | Since |
|---|---|---|---|
Soo In Hwang
FOU | Founder | 64 | 18-12-18 |
Raquel Izumi
FOU | Founder | 54 | 18-12-18 |
Tom Thomas
FOU | Founder | 64 | 18-12-18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ahmed Hamdy
CEO | Chief Executive Officer | 59 | 18-12-18 |
Laura Bushnell
BRD | Director/Board Member | 56 | 20-12-22 |
Brian Druker
BRD | Director/Board Member | 68 | 20-12-22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 0.72 | -3.73% | 200,415 |
| 24-05-15 | 0.7479 | -2.18% | 295,352 |
| 24-05-14 | 0.7646 | +0.61% | 256,345 |
| 24-05-13 | 0.76 | -5.30% | 464,942 |
| 24-05-10 | 0.8025 | -5.59% | 434,432 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotes
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. It has a next generation bioconjugation platform, called VersAptx. The VersAptx platform is a versatile and adaptable, next generation bioconjugation platform. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (P-TEFb/CDK9 inhibitor). VIP943 is a potential anti-CD123 ADC created with its VersAptx Platform. It consists of an anti-CD123 antibody, a novel legumain-cleavable linker, and a KSPi payload enhanced with its CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.
Calendar
2024-05-23
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.72
USD
Average target price
9
USD
Spread / Average Target
+1,150.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.98% | 21.26M | |
| +8.29% | 114B | |
| +10.21% | 104B | |
| +0.58% | 22.28B | |
| -11.90% | 22.41B | |
| -5.57% | 19.07B | |
| -37.36% | 18B | |
| -5.17% | 17.89B | |
| +7.70% | 14.28B | |
| +37.65% | 12.55B |
- Stock Market
- Equities
- VINC Stock
